Revelation Biosciences, Inc. (REVB)

NASDAQ: REVB · Real-Time Price · USD

1.220

+0.030 (2.52%)

At close: Mar 23, 2026, 4:00 PM EDT

1.220

0.00 (0.00%)

Pre-market: Mar 24, 2026, 8:43 AM EDT

Revelation Biosciences Employees

Revelation Biosciences had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.

Employees

9

Change (1Y)

-1

Growth (1Y)

-10.00%

Revenue / Employee

n/a

Profits / Employee

-$1,651,686

Market Cap

4.54M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)	Full-Time	Part-Time
Dec 31, 2024	9	-1	-10.00%	8	1
Dec 31, 2023	10	4	66.67%	9	1
Dec 31, 2022	6	-	-	6	0

Related Stocks

Company Name	Employees
Aptevo Therapeutics	37
Quince Therapeutics	36
VivoSim Labs	14
Genprex	13
Biodexa Pharmaceuticals	13
Azitra	12
Akari Therapeutics,	9
Matinas BioPharma Holdings	3

Employee Rankings

REVB News

5 days ago - Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference - Accesswire
25 days ago - Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 - Accesswire
2 months ago - Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Accesswire
2 months ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Accesswire
2 months ago - Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - Accesswire
2 months ago - Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - Accesswire
2 months ago - Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
2 months ago - Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Accesswire